Insulin resistance in obesity: an overview of fundamental alterations by R. Barazzoni et al.
 1 
INSULIN RESISTANCE IN OBESITY – An overview of fundamental alterations 
 
Rocco Barazzonia*, Gianluca Gortan Cappellaria, Maurizio Ragnib, Enzo Nisolib* 
 
aDepartment of Medical, Surgical and Health Sciences – University of Trieste, Trieste, Italy and 
Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Trieste, Italy; bCentre for Study and 
Research on Obesity, Department of Medical Biotechnology and Translational Medicine, University 
of Milan, Milan, Italy. *co-corresponding authors. 
 
 
 
 
 
Correspondence addresses (co-corresponding authors): 
Rocco Barazzoni 
University of Trieste  
Department of Medical Sciences 
Strada di Fiume, 447 
34149 Trieste, Italy 
Phone: 39-040-3994416 
Fax: 39-040-3994593 
e-mail: barazzon@units.it  
 
Enzo Nisoli  
University of Milan 
Center for Study and Research on Obesity 
Department of Medical Biotechnology and Translational Medicine 
Via Vanvitelli, 32 
20129 Milano, Italy 
Tel: +39 02 50317116 
Email: enzo.nisoli@unimi.it 
 
Word Count: 2892 
Number of tables: 0, Figures: 2 
  
 2 
ABSTRACT 
 
 
Obesity is a major health risk factor, and obesity-induced morbidity and complications account for 
huge costs for affected individuals, families, healthcare systems and society at large. In particular, 
obesity is strongly associated with the development of insulin resistance, which in turn plays a key 
role in the pathogenesis of obesity-associated cardiometabolic complications, including metabolic 
syndrome components, type 2 diabetes and cardiovascular diseases. Insulin sensitive tissues, 
including adipose tissue, skeletal muscle and liver are profoundly affected by obesity both at 
biomolecular and functional levels. Altered adipose organ function may play a fundamental 
pathogenetic role once fat accumulation has ensued. Modulation of insulin sensitivity appears to 
be, at least in part, related to changes in redox balance and oxidative stress as well as 
inflammation, with a relevant underlying role for mitochondrial dysfunction that may exacerbate 
these alterations. Nutrients and substrates as well as systems involved in host-nutrient 
interactions, including gut microbiota, have been also identified as modulators of metabolic 
pathways controlling insulin action. This review aims at providing an overview of these concepts 
and their potential inter-relationships in the development of insulin resistance, with particular 
regard to changes in adipose organ and skeletal muscle.  
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1. Definition of insulin resistance 
Besides its pivotal role in the regulation of intermediate substrate metabolism, insulin also 
regulates a wide range of fundamental cell and organ functions that largely fall beyond the scope 
of this work [1-3]. The main physiological impact of insulin in the regulation of nutrient utilization 
and intermediate metabolism occurs in the post-prandial state, when variable rises in plasma 
glucose trigger insulin secretion [4,5]. This leads in turn to plasma glucose clearance by stimulating 
its uptake and utilization by skeletal muscle and adipose tissue, and by blunting hepatic glucose 
output through inhibition of liver gluconeogenesis and glycogenolysis. Major insulin actions also 
result in preservation of skeletal muscle mass through inhibition of protein breakdown and 
translation of specific protein groups [6,7], and in induction of lipid storage in adipose tissue [5]. 
Although any impairment of insulin effects on target tissues could be labelled as insulin resistance, 
in clinical practice the latter commonly identifies reduced insulin action on glucose metabolism. It 
should be conversely pointed out that individuals defined as insulin resistant for glucose 
metabolism may present less impaired or normal insulin action on other important biological 
targets. Indeed, the presence and time course of changes in insulin effects on protein turnover 
and lipid metabolic pathways in various tissues in obese insulin resistant individuals remains 
largely to be defined and represents a relevant question for basic and clinical research [8-10]. The 
current review will however focus on the commonly defined insulin resistance in terms of glucose 
metabolism and its consequences on glucose levels and major cardiometabolic risk factors.  
 
2. Obesity and insulin resistance 
Obesity is one of the most important risk factor for health and its cardiometabolic complications, 
including insulin resistance, metabolic syndrome components, type 2 diabetes and cardiovascular 
disease, represent a huge burden for affected individuals, healthcare systems and society at large 
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[11]. The American Medical Association (AMA), the largest physician organization in the United 
States has indeed recently issued a declaration characterizing obesity as a disease in its own right 
[12]. While the negative impact of obesity on human health is strongly established, it should be 
pointed out that development of metabolic and cardiovascular complications is not inevitable in 
obese individuals [13]. From both clinical and epidemiological points of view, it is therefore of 
pivotal importance to identify obese individuals at higher risk of obesity-associated diseases, since 
this would allow more effective utilization of limited resources for intensive therapeutic 
approaches. In recent years, the direct role of insulin resistance in the development of metabolic 
and cardiovascular complications even beyond type 2 diabetes has become increasingly clear, as 
exemplified by its major pathogenetic impact on the onset of metabolic syndrome [14]. Although 
clinical features contributing to the definition of metabolic syndrome may vary, there is indeed a 
general agreement on the involvement of abdominal obesity and insulin resistance in the 
development of lipid abnormalities and high blood pressure that commonly identify the syndrome 
and contribute to its negative impact on cardiometabolic disease along with high blood glucose 
[14]. In the present review, we will aim at providing an overview of current knowledge on major 
causes linking obesity to the onset of insulin resistance.   
 
3. Causes of insulin resistance in obese individuals 
Although obesity is not invariably associated with insulin resistance, a large majority of insulin 
resistant individuals is obese or overweight [13,11]. Obesity is therefore a fundamental risk factor 
for the onset and development of insulin resistance. Among possible causes of obesity-induced 
metabolic derangements, adipose organ dysfunction and altered adipose metabolic processes 
clearly play a fundamental role [15,16]. Oxidative stress resulting from imbalanced reactive oxygen 
species (ROS) generation and antioxidant defences as well as chronic inflammation in non-adipose 
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tissues are also major regulators of insulin sensitivity [1,17-24]; in particular, elevated pro-
inflammatory stimuli may be enhanced by excess ROS and directly impair insulin signalling in 
insulin target tissues [1,17,18,25-27]. Complex systemic networks including responses to nutrients 
and substrates, the gut and its microbiota are also key players acting by regulating substrate 
utilization and balance, thereby modulating oxidizing and inflammatory stimuli [28,29].  
 
3.1 Adipose organ dysfunction 
Adipokines and adipose endocrine function 
It is largely demonstrated that adipocytes secrete several hormones (collectively defined as 
adipokines or adipocytokines) with a large array of biological effects on metabolism, inflammation 
and haemostasis, thereby modifying the classical and currently obsolete view of adipose tissue as 
an inert fat storage tissue [15,30,16]. Describing the complexity of adipose endocrine functions is 
beyond the scope of this work; among better-characterized hormones with well-established 
clinical associations with insulin action, adiponectin is positively associated with insulin sensitivity 
and lower risk for metabolic syndrome and cardiometabolic diseases and it very well exemplifies 
adipose-derived metabolically beneficial hormones [30,16]. In particular, adiponectin has been 
shown to increase lean tissue lipid oxidation and mitochondrial function [31] by means of 
activation of AMP-activated protein kinase (AMPK), one major stimulator of substrate utilization 
and metabolism [32,31]. On the other hand, adipocytes secrete pro-inflammatory cytokines 
including TNF-alpha and IL-6, that may activate inflammatory responses both locally and 
systemically with negative systemic metabolic impact [33]. Caloric restriction and obesity 
importantly elicit opposite changes in adipocytokine secretion levels and patterns [34,33]. While 
obesity is characterized by low adiponectin levels and high adipose organ secretion of TNF-alpha 
and other proinflammatory cytokines, caloric restriction and fat loss may at least partly reverse 
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this alteration [34,33]. Although mechanisms controlling adipokine secretion have not been 
completely elucidated, adipose oxidative stress and organ plasticity are proposed to play key 
regulatory roles.  
 
Oxidative stress – Adipocyte oxidative stress has been demonstrated both in vivo and in vitro to 
lead to secretion of metabolically harmful adipocytokine patterns [35]. Of note, in classic studies 
adiponectin expression was lower and IL-6 expression was increased in adipocytes after induction 
of oxidative stress; antioxidant treatment notably reversed these changes [35]. Plasma 
adiponectin levels have been also found to be negatively associated with circulating lipid 
peroxidation markers in humans with chronic kidney disease [36]. Primary stimuli leading to 
adipose and systemic oxidative stress in obesity remain incompletely defined but may include 
excess lipid as well as glucose substrate availability from dietary and non-dietary sources [37]. 
Similar to non-adipose tissues and organs that will be discussed below, emerging evidence 
indicates that mitochondrial dysfunction may also characterize dysfunctional adipocytes in obesity 
and may play a key role in ROS overproduction [38]. Additional systems have been however 
identified to contribute to oxidative stress, including NADPH oxidase [39,35].  
 
Adipose organ plasticity – Expansion of adipose mass is the hallmark of obesity. Paradoxically, 
recent reports however show that the ability to increase adipose mass during excess energy intake 
and positive energy balance actually leads to more favourable metabolic outcomes [40]. More 
effective lipid storage in adipocytes could at least in part explain this apparently counterintuitive 
observation; higher adipocytes lipid uptake would indeed prevent ectopic lipid deposition in non-
adipose tissues, which could instead result in derangement of insulin action and cell metabolism 
[15]. Least harmful metabolic patterns are indeed associated with adipose organ growth in 
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response to excess energy intake through enhanced adipocytes differentiation and proliferation 
[40]. Conversely and importantly, inability to stimulate proliferation may result in adipocyte 
hypertrophy leading to cell damage, death through apoptosis and pyroptosis [41] and increased 
local and systemic inflammation due to macrophage recruitment and activation [42]. Although 
adipocytes proliferation, number and size are difficult to routinely measure in vivo in clinical 
studies, available evidence strongly supports the concept that these parameters contribute to 
define metabolic phenotypes including insulin resistance in obese individuals [43,44]. As a 
clinically relevant and well-established example, the well-known insulin sensitizing effect of 
antidiabetic drugs thiazolidinediones appears to involve at least in part their ability to stimulate 
adipocyte differentiation through PPARgamma activity [45]. Investigation of mechanisms 
regulating adipocyte differentiation and proliferation during adipose mass expansion are therefore 
undoubtedly of potential great interest and clinical impact. In particular, uncovering hormonal and 
nutritional regulatory mechanisms will enhance potential for effective therapeutic strategies 
aimed at preventing obesity-associated metabolic complications.  
 
Adipose organ thermogenesis 
Enhancing energy expenditure through increased metabolic inefficiency and heat production from 
mitochondrial uncoupling during substrate oxidation is also an emerging promising strategy in 
both prevention and treatment of obesity and metabolic syndrome, following the discovery that 
brown adipose tissue (BAT) deposits exist and their metabolic activity could be modulated in adult 
humans [46,47]. Both cold exposure and physical exercise, two classical mediators of increased 
energy expenditure, have been indeed shown to promote conversion of white into brown 
adipocytes; browning is also notably and accordingly reported to be increased by thyroid hormone 
and may be blunted by cortisol, although with possible species-specific differences [48-51]. 
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PRDM16 has been identified as one major transcription factor involved in these processes in 
experimental models; relevant to the topic of this review, PRDM16 manipulation also results in 
enhanced glucose tolerance and improved metabolic phenotype [46]. Additional reports have 
shown that irisin, a myokine secreted following exercise, could have a browning effect [46], and 
potential transition from muscle cells into brown adipocytes has been also described [46,47]. Most 
intriguingly and importantly, reports of impaired BAT activation in obesity are available [52,53] 
and this potential fundamental alteration could therefore primarily contribute to both positive 
energy balance and metabolic complications including insulin resistance. Potential differential 
mechanisms regulating adipocyte thermogenesis in rodent experimental models and humans will 
require further investigation.  
 
3.2 Substrate availability 
Excess lipid substrates and lipotoxicity 
Excess caloric intake, as commonly induced by high-fat/high-calorie western diets may directly 
trigger both oxidative stress and inflammation at tissue and systemic levels [25,54,55]; lipid  
substrates have been notably more extensively studied compared to glucose and will therefore 
represent the main focus of this section. Triglyceride i.v. infusion leading to high circulating fatty 
acids comparable to those observed following a high-fat meal directly causes systemic insulin 
resistance in humans and experimental models [56-60], and elevated plasma free fatty acids are 
common in obese individuals (40,41) due to both potential elevated dietary intake and enhanced 
lipolysis from adipocytes. Fatty acids levels importantly cause inflammation and oxidative stress in 
vitro in muscle cell cultures [61-63]; inflammation and oxidative stress along with additional 
mechanisms including endoplasmic reticulum stress are accordingly among proposed 
pathogenetic derangements linking excess fatty acid availability with insulin resistance 
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[1,57,58,61,60,64,65]. Under conditions of chronic excess fat availability with development of 
overweight or obesity, lipotoxicity and insulin resistance may chronically result through different 
mechanisms from lipid deposition in non-adipose insulin target tissues [59]. Intracellular 
triglyceride accumulation in both skeletal muscle and liver has indeed been long recognized to be 
associated with tissue and systemic insulin resistance [66,67]. Dyacyl-glycerol has been specifically 
shown to promote muscle insulin resistance by further impairing subsequent fat oxidation through 
negative feedback mechanisms [65]. Further clarification on how intracellular lipids impair insulin 
signalling came from more recent reports indicating excess saturated fatty acid availability as a 
source of excess ceramide and sphingolipids in skeletal muscle [68,69], in turn leading to impaired 
insulin signalling and insulin resistance. The process was further reported to be enhanced by pro-
inflammatory changes, thereby unveiling potential vicious cycles linking fat, inflammation and 
metabolic dysfunction [68] (Figure 1).  
 
A majority of in vitro studies demonstrating metabolically harmful effects of fatty acids in muscle 
cells utilized the saturated fatty acid palmitate; saturated fat has been consistently proposed to 
play a key role in deleterious metabolic effects of lipids [61-63]. Differential and potentially 
beneficial activities of unsaturated fatty acids, with particular regard to polyunsaturated n-3 
moieties, have been conversely proposed also in terms of impact on insulin resistance and 
metabolic disease [70,71,63]. Direct relationships between chronic or acute elevation of both total 
and saturated fatty acids and oxidative stress, inflammation and insulin resistance has been 
reported in human studies [72,64,65,71,70,60], whereas protective effects of polyunsaturated n-3 
fatty acids have emerged [70,71]. Recent evidence however also indicated that acute increments 
in saturated and monounsaturated circulating fatty acids through i.v. infusion in the presence of 
physiological hyperinsulinemia directly caused skeletal muscle and systemic insulin resistance 
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through enhanced mitochondrial ROS production and IKB-NF-kB pathway activation in rodents [1]. 
These observations directly suggest that at least under the above acute experimental conditions, 
saturated fatty acids may not be solely responsible of fat-induced metabolic derangements in vivo 
[1]. Albeit less investigated, the involvement of glucose metabolism in inflammation and oxidative 
stress particularly at skeletal muscle level is supported by both clinical observations in patients 
with diabetes mellitus and by experimental models. These reports indicate a pro-oxidant and pro-
inflammatory role for glucose elevation [73], and moderate glucose fluctuations potentially 
reaching hyperglycaemic levels at least during post-prandial conditions could therefore contribute 
to the onset of obesity-induced insulin resistance.  
 
Mitochondrial dysfunction 
Over the last decades, associations between obesity, insulin resistance and low skeletal muscle 
mitochondrial function and ATP production capacity have been reported [74,75,19,76,77]. In 
humans, lower expression of the key regulator of muscle mitochondrial biogenesis PGC1α as well 
as reduced mitochondrial function have been described in progeny and first degree relatives of 
diabetic and insulin resistant patients [78,74]. Mitochondrial dynamics including balanced 
organelle fission and fusion may also be affected by excess fat, which may enhance mitochondrial 
fission and fragmentation with consequent organelle dysfunction [79]. Importantly, mitochondrial 
dysfunction may be a direct consequence of pro-inflammatory signalling and oxidative stress, both 
characterizing metabolically complicated obesity [80,81]. Altered mitochondrial dynamics and 
function in skeletal muscle may therefore represent relatively late and not primary-causal 
alterations in obese individuals [82-86]; once established, mitochondrial derangements have 
however substantial potential to synergistically worsen oxidative stress, inflammation and insulin 
resistance by promoting further increments in ROS production. In addition, impaired 
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mitochondrial fatty acid oxidative metabolism may worsen fatty acid accumulation and lipotoxicity 
[74,17,18] (Figure 2).  More recently, an impairment of the process of autophagy, the quality 
control mechanism promoting renewal of intracellular damaged proteins and organelles, including 
mitochondria (i.e. mitophagy) has been reported in rodent models of obesity, diabetes and insulin 
resistance [18,87,17]; these alterations have been tissue-specifically reported at skeletal muscle 
level and could directly contribute to accumulation of dysfunctional mitochondria. Although these 
hypotheses require further confirmation, enhancing or restoring defective autophagy could 
become an additional promising approach for improvement of mitochondrial quality and activity, 
with potential positive impact on oxidative stress and insulin action at least in skeletal muscle 
tissue. It should indeed be pointed out that differential changes in energy metabolism gene 
expression have been conversely intriguingly reported in the liver in obese insulin resistant 
individuals [88,89]; such observations further underscore the complex interplay between obesity, 
energy metabolism and mechanisms underlying metabolic complications, whose tissue-specificity 
will require systematic investigation. 
 
3.3 Host-nutrient interactions – The case of gut microbiota 
Growing evidence indicates gut microbiota as a key player in the regulation of host-substrates  
interactions, with particularly regard to metabolic responses to food intake [28,29,90-92]. It is 
indeed widely accepted that differential metabolic and energy balance-modulating responses to 
nutrient intake are affected by gut microbiota composition. Consistent with deleterious metabolic 
impact of specific bacterial phyla in metabolic regulation, germ-free animals are protected from 
diet-induced obesity [93,90]. High heterogeneity in human gut bacteria has been however found 
to be protective and associated to lower risk of obesity and related diseases, while higher risk to 
develop obesity was associated with less heterogeneous phyla [94]. Of note, as shown by gene 
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cluster analysis, dietary restriction is also able to modulate gut microbiota [95] and this process 
involves increasing abundance of bacterial phyla, that may be reversed upon restoration of 
normal-calorie diet [96]. Remarkably, diet-induced metabolic derangements that are directly 
involved in the onset of insulin resistance, also independently from obesity, have been reported to 
be directly modulated and at least in part mediated by gut bacterial metabolism in experimental 
models [97]. Strong evidence indeed indicates that excess consumption of diets enriched in 
saturated fat leads to increased bacterial production of proinflammatory lipopolysaccharide as 
well as gut permeability that allows for enhancement of systemic inflammation [97]. Overall, the 
concept of metabolic endotoxemia has emerged, representing a potential key diet-modulated 
contributor to obesity-associated metabolic derangements including insulin resistance [97]. From 
a mechanistic point of view, bacterial production levels of short chain fatty acids (SCFA) in 
response to nutrient-lipid intake appears to play a major role in the ability of gut microbiota to 
positively modulate energy balance and metabolism [93,98].  
 
4. Conclusions 
Insulin resistance, i.e. a lower that normally expected impact of insulin on glucose metabolism and 
plasma levels at any given insulin concentration, has increasing prevalence and incidence in 
humans mainly due to corresponding increments in obesity levels, with substantial impact on 
human disease. The pathophysiology of insulin resistance is complex and still incompletely 
understood. Fat accumulation with particular regard to visceral adiposity and ectopic lipid 
deposition in extra-adipose tissues may independently sustain metabolic abnormalities through 
chronically altered, pro-inflammatory and insulin-desensitizing signals from dysfunctional adipose 
organ. Tissue inflammation and oxidative stress may be sustained by the onset of metabolically-
induced mitochondrial dysfunction, potentially resulting in metabolic vicious cycles. The latter may 
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be also directly triggered by acute and chronic exposure to high nutrients and substrates per se, at 
least partly independent of excess body fat mass. In particular, complex heterogeneous 
mechanisms underlying metabolically harmful effects of lipid substrates, that appear to include 
negative interaction with gut microbiota,  play a central role in linking diet, obesity and insulin 
resistance. Increasing knowledge on metabolic and organ networks underlying and sustaining 
insulin resistance, the role of substrates and the key involvement of adipose organ dysfunction 
should be strongly pursued for its major potential to reduce the burden of obesity-associated 
metabolic and cardiovascular complications. 
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FIGURE LEGEND 
Fig. 1 Putative mechanisms contributing to negative effects of Free Fatty Acids (FFA), and their 
saturated fraction, on tissue and systemic insulin sensitivity. DAG: di-acyl glycerol; ER: endoplasmic 
reticulum. 
Fig. 2 Putative clustered metabolic derangements contributing to obesity-induced skeletal muscle 
insulin resistance 
 
  
 


